Maryland House Committee to Hear Decriminalization and Legalization Bills, Advocates to Rally in SupportMarch 12, 2014
Tomorrow, the Maryland House Judiciary Committee will be holding a public hearing to discuss House Bill 880 (legalization) and House Bill 879 (decriminalization) at 1:00pm in Annapolis.
Maryland residents can click here to contact their legislators in favor of decriminalization and here to contact them in favor of legalization. It only takes a few minutes, so please take a moment of your time to let your voice be heard.
Please also consider calling both House Judiciary Committee Chairman Delegate Vallario and Speaker of the House Delegate Busch to let them know that Marylanders support reforming the state’s marijuana policies. These two will be key in seeing these measures advance and have had prior history of opposing such efforts. Their contact information is below:
House Judiciary Committee Vallario
Speaker of the House Delegate Busch
Prior to the hearing, marijuana law reform advocates will be rallying at Lawyers Mall outside of the state house at 11:00am to show support for these important pieces of legislation. They will be joined by legalization and decriminalization bill sponsor, and NORML PAC endorsed candidate for Maryland Governor, Delegate Heather Mizeur. More information on the rally is available here.
Thank you for supporting our efforts to legalize marijuana in Maryland. Together, we can bring about great change in the state this legislative session!
Retail sales of cannabis in the month of January yielded an estimated $3.5 million dollars in state tax revenues, according to financial data released online this week by the Colorado Department of Revenue.
Under Colorado law, commercial cannabis producers must pay a 15 percent excise tax, while retail customers must pay an additional ten percent sales tax (on top of the state’s existing 2.9 percent sales tax) on any cannabis purchased at a licensed facility. The majority of Colorado voters approved the imposition of cannabis-specific taxes (Proposition AA) in November 2013.
For the month, customers spent an estimated $14 million on the purchase of marijuana and cannabis-infused goods at state-licensed facilities. This figure is anticipated to grow larger as more and more facilities become operational.
State law authorized the retail sale of cannabis beginning on January 1st to those age 21 or older. At that time, only 24 retailers were operational. By month’s end, nearly 60 facilities were up and running. Presently, over 150 licensed facilities are operational.
Similarly licensed retail operations are anticipated to be operational in Washington by this summer.
In recent weeks, lawmakers in several states have moved forward with legislative proposals to permit specific strains and/or extracts of cannabis possessing high quantities of the cannabinoid cannabidiol (CBD), but otherwise maintaining criminal prohibitions on the whole plant.
But is this new direction in the best interest of patients? As I wrote in a recent column for Alternet.org (republished with permission by Cannabis Now under the title “Patients Ought To Be Skeptical Of Proposed CBD-Only Legislation — Here’s Why”), I believe the answer is ‘no.’
Ultimately, patients should not be unnecessarily forced to decide between either accessing the whole plant or its isolated components. They should have safe, legal access to both, and politicians, even well-intentioned ones, should not restrict patients’ right to choose the most suitable option.
Below are excerpts from my commentary. You can read the entire text here.
Patients Ought To Be Skeptical Of Proposed CBD-Only Legislation — Here’s Why
via Cannabis Now
[excerpt] If the plant ain’t broke, why fix it?
For longtime marijuana law reformers, the ongoing political conversation surrounding CBD is instructive. It makes it clear that many politicians’ public opposition to the idea of patients using marijuana therapeutically isn’t because of supposed unanswered questions surrounding the plant’s safety or efficacy. Rather, it is because lawmakers oppose the idea of some people getting high from a naturally growing herb. (The fact that patients can get equally high or even higher from FDA-approved synthetic THC has, for whatever reason, never been an expressed concern of either lawmakers or prohibitionists.) After all, the very same politicians who argue that marijuana isn’t medicine because it hasn’t been approved by the FDA or who allege that the substance hasn’t yet been subjected to sufficient scientific scrutiny utter no such public objections to the idea of legalizing patient access to CBD – a schedule I compound that hasn’t been reviewed, much less approved by the FDA, and that has been clinically studied far less than cannabis.
Perhaps most ironically is that were it not for the advent of legalized whole plant marijuana, a policy change publicly opposed by many present day CBD-only political advocates, lawmakers (and anti-pot groups like SAM) today wouldn’t be aware of CBD, much less advocating for it. The reality is that it was the stakeholders in medical marijuana states, and those who provide for them, who have done the most to explore and promote cannabidiol as a legitimate therapeutic agent. And they were able to do so because they, unlike most federally licensed medical researchers, had access to the whole plant.
We’ve been down this road before. Not long ago, lawmakers and anti-marijuana zealots were dismissing patients’ desire to access the marijuana plant because they alleged that the THC-pill Marinol could adequately meet patients’ needs. Patients and their advocates were skeptical of lawmakers’ claims then, and properly so. Now many of these same politicians are once again dismissing patients’ calls for whole plant medicine by claiming that products and strains containing CBD alone only will suffice. Patients and their advocates ought to be equally skeptical once again.
On Sunday February 16th, I bought legal weed for the first time from a recreational cannabis store in Denver, Co. I spent a few minutes speaking with some of the employees, as I was eager to hear how things were going under this newly sanctioned marijuana market. Unsurprisingly, business was great. Some items were selling quicker than others, but everyone was in agreement that the rollout of Colorado’s legal cannabis retail system had been a great success, except for one crucial component that was as unsettling as it was expected – we were standing in one of a few dozen high profile stores, well-known for having excessive amounts of cash on hand (in the first week of sales, businesses generated $5 million in cash-only transactions) and no where to put it, because the banks won’t take it.
Clearly, denying these pot stores the ability to safely deposit their earnings poses an imminent threat to public safety. These shops are easy targets for robbery and assault (as well as other forms of criminal activity), which puts customers and employees at serious risk. Some of these shop owners are considering banning backpacks or other large bags – others are arming their workers. Neither of these options are a viable solution.
This problem isn’t new however, nor is it going unnoticed. On February 14th, the Department of Treasury released a nonbinding memorandum, in conjunction with the Justice Department stating that banks may consider working with pot retailers without fear of prosecution – so long as they remain in compliance with state laws, and followed other instructions outlined in the memo. Though a truly historic and progressive action by the federal government’s leading financial regulatory body, these guidelines are largely symbolic, providing no actual legal protection to banks working with cannabis shops. As such, most financial companies remain skeptical about getting involved with a market existing under so many contradictory laws.
According to federal law, these banks could technically be found guilty of money laundering (among other offenses) for handling the proceeds of what the US government still considers an illegal drug. The Colorado Bankers Association rightly notes that the guidance issued by the Department of Justice and the U.S. Treasury “only reinforces and reiterates that banks can be prosecuted for providing accounts to marijuana related businesses.” The Association further criticizes these new guidelines, stating that “Bankers had expected the guidance to relieve them of the threat of prosecution should they open accounts for marijuana businesses, but the guidance does not do that. Instead, it reiterates reasons for prosecution and is simply a modified reporting system for banks to use. It imposes a heavy burden on them to know and control their customers’ activities, and those of their customers.”
Is it any surprise then that these guidelines – which include a multi-tiered labeling structure and a requirement for banks to maintain ‘suspicious activity reports’ – have left many financial institutions with cold feet? Two of Colorado’s largest banks, Wells Fargo and FirstBank have already announced they won’t work with weed-related enterprises. In fact, most financial trade associations have widely rejected these latest overtures because there are no tangible, legal policies in place.
Despite the skepticism held by many federal administration officials and other politicians, the government can and should be doing much more to enable the success of this new, legal market. Unfortunately, many are sitting on their hands, and holding their breath – hoping to quietly ride out this growing wave of support for legalization, which shows no sign of subsiding. Over 50% of the US population supports a regulated marijuana retail system for adults.
Its time for these officials to concede to the will of the electorate, and address the legitimate needs of this new industry. Lawmakers now have an opportunity to show true leadership in this changing political landscape by supporting legislation that would give states and businesses the resources necessary to enable a responsible and successful implementation of this new “great experiment.” Specifically, they should get behind the “Marijuana Businesses Access to Banking Act,” introduced by Colorado representative Ed Perlmutter. This bill (HR 2652), already endorsed by the Colorado Bankers Association, would alter various banking laws to protect banks providing services to marijuana-related businesses from the threat of federal prosecution and other penalties.
Financial institutions don’t operate off good-faith statements (including non-binding memorandums) – even those from the Department of Treasury, or any other enforcement agency. They operate under explicit legal authorization. Only when the laws change will the banks truly be free to provide the services these businesses so desperately need, and their communities rightly deserve.
Contact your representative today and tell them to support HR 2652
CNN Chief Medical Correspondent Dr. Sanjay Gupta is “doubling down” in his advocacy for patients to have legal access to cannabis as a therapeutic agent.
In a commentary featured on the CNN website today, Gupta writes: “I am more convinced than ever that it is irresponsible to not provide the best care we can, care that often may involve marijuana. I am not backing down on medical marijuana; I am doubling down.”
Last August, Gupta authored a commentary apologizing for his past opposition to medical cannabis, stating, “We have been terribly and systematically misled for nearly 70 years in the United States (in regards to cannabis), and I apologize for my own role in that.”
In today’s editorial, Gupta acknowledges, “Marijuana is classified as a Schedule I substance, defined as (one of) the most dangerous drugs with no currently accepted medical use. Neither of those statements has ever been factual.”
He criticizes President Obama for acknowledging that cannabis poses less harm than alcohol while failing “to remove marijuana from the list of the most tightly controlled substances in the country.” Dr. Gupta also questions how the US government can possess a patent on the therapeutic application of cannabinoids yet still deny that the compounds possess medical utility.
Ultimately, cannabis prohibition is a “Draconian system where politics override science,” Gupta concludes.
Gupta’s forthcoming documentary on the plant, entitled “Weed 2: Cannabis Madness: Dr. Sanjay Gupta Reports,” at 10 p.m. ET on Tuesday, March 11.